Fasting-mimicking diet (ProLon-style 5-day cycles)

There is genuine randomised human trial evidence, which puts FMD ahead of most longevity protocols, but the strongest claims are the weakest supported. The anchor trial (Wei et al., Sci Transl Med 2017) showed improvements in cardiometabolic risk markers after three monthly cycles in generally healthy adults. The most clinically solid result is a 12-month randomised trial in Dutch primary care (van den Burg et al., Diabetologia 2024) showing reduced medication need and improved glycaemic control in type 2 diabetes. A phase 2 randomised trial (DIRECT, Nat Commun 2020) tested FMD alongside neoadjuvant chemotherapy in breast cancer, and a 2026 Nature Medicine RCT tested it in mild-to-moderate Crohn's disease. What the evidence does NOT show: no trial has demonstrated an effect on mortality, incident disease, or any hard longevity outcome. The widely marketed "2.5 years younger" figure comes from Brandhorst et al. (Nat Commun 2024), which was a secondary and exploratory analysis of blood samples from two prior trials, with 61 of 100 enrolled participants completing the protocol, and whose own abstract describes the findings as preliminary. Biological-age clocks are surrogate measures, not outcomes. Much of the trial literature originates from or is connected to the Longo group and L-Nutra, the company that sells ProLon, and independent replication of the ageing claims is thin. Marketing on ProLon's own site ("the only program to trigger autophagy in humans", "reduce your biological age") materially overstates what the trials establish. NEGATIVE FINDING on regional availability: no Singapore or Australian clinic on the supplied lists was found advertising FMD or ProLon on its own site. Chi Longevity, the closest SG candidate, lists gut health, glucose, biological age snapshot, weight management and gene-based nutrition programmes, with no fasting-mimicking protocol. Do not publish an SG or AU availability claim without direct clinic-page confirmation. NOTE ON METHOD: this session's live web search budget was exhausted before I could query the HSA and TGA sites directly. Both regulatory fields are therefore returned as null rather than guessed. The only regulatory statement I retrieved is US-specific: ProLon's own site carries the standard FDA disclaimer that its statements are not FDA-evaluated and the product is not intended to diagnose, treat, cure or prevent disease, and describes its ingredients as GRAS. That indicates a food-supplement framing in the US and says nothing verifiable about HSA or TGA classification.

What it is

Plain-language explainer

Categories